New meta-analysis.
"Seven eligible cohort studies with 7,808 participants were included."
"... an increment of every 20 nmol/L {8 ng/mL} in circulating vitamin D level was" associated with a 9% reduction in mortality.
-Patrick
ncbi.nlm.nih.gov/pubmed/303...
Endocr Connect. 2018 Oct 1. pii: /journals/ec/aop/ec-18-0283.xml. doi: 10.1530/EC-18-0283. [Epub ahead of print]
Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis.
Song Z1, Yao Q2, Zhuo Z3, Ma Z4, Chen G5.
Author information
1
Z Song, Department of Urology, Jinshan Hospital of Fudan University, Shanghai, China.
2
Q Yao, Department of Endocrinology, Department of Endocrinology, Jinshan Hospital of Fudan University, 1508 Longhang Road, Shanghai 201508, China, Shanghai, 201508, China.
3
Z Zhuo, Shanghai, China.
4
Z Ma, Shanghai, China.
5
G Chen, Shanghai, China.
Abstract
BACKGROUND:
Previous studies investigating the association of circulating 25-hydroxyvitamin D level with prognosis of prostate cancer yielded controversial results. We conducted a dose-response meta-analysis to elucidate the relationship.
METHODS:
PubMed and Embase were searched for eligible studies up to July 15, 2018. We performed a dose-response meta-analysis using random-effect model to calculate the summary hazard ratio (HR) and 95% confidence interval (CI) of mortality in patients with prostate cancer.
RESULTS:
Seven eligible cohort studies with 7,808 participants were included. The results indicated that higher vitamin D level could reduce the risk of death among prostate cancer patients. The summary HR of prostate cancer-specific mortality correlated with an increment of every 20 nmol/L in circulating vitamin D level was 0.91, with 95% CI 0.87-0.97, P=0.002. The HR for all-cause mortality with the increase of 20 nmol/L vitamin D was 0.91 (95% CI: 0.84-0.98, P=0.01). Sensitivity analysis suggested the pooled HRs were stable and not obviously changed by any single study. No evidence of publications bias was observed.
CONCLUSION:
This meta-analysis suggested that higher 25-hydroxyvitamin D level was associated with a reduction of mortality in prostate cancer patients and vitamin D is an important protective factor in the progression and prognosis of prostate cancer.
PMID: 30352424 DOI: 10.1530/EC-18-0283